Atossa Therapeutics Inc (NASDAQ: ATOS) Gets A Nod To Start The Phase 2 Clinical Study Of Oral Endoxifen

The stock of Atossa Therapeutics Inc (NASDAQ: ATOS) rose to $4.31.The Swedish Medical Product Agency (MPA) has paved the way for the company to embark on its Phase 2 clinical study. The body gave its approval to the clinical-stage biopharmaceutical company, marking the initiation of efforts geared towards discovering the effectiveness […]